Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients.

MLA

Wang, Chao, et al. “Combining UBR5 and CD163+ Tumor-Associated Macrophages Better Predicts Prognosis of Clear Cell Renal Cell Carcinoma Patients.” Cancer Immunology, Immunotherapy, vol. 70, no. 10, Oct. 2021, pp. 2925–35. EBSCOhost, https://doi.org/10.1007/s00262-021-02885-9.

APA

Wang, C., Hong, T., Wang, Y., Peng, G., Yu, Y., Zhang, J., Zhuo, D., Zheng, J., Ma, X., & Cui, X. (2021). Combining UBR5 and CD163+ tumor-associated macrophages better predicts prognosis of clear cell renal cell carcinoma patients. Cancer Immunology, Immunotherapy, 70(10), 2925–2935. https://doi.org/10.1007/s00262-021-02885-9

Chicago

Wang, Chao, TianYu Hong, Yuning Wang, Guang Peng, Yongwei Yu, Jing Zhang, Dong Zhuo, Jingcun Zheng, Xiaojing Ma, and Xingang Cui. 2021. “Combining UBR5 and CD163+ Tumor-Associated Macrophages Better Predicts Prognosis of Clear Cell Renal Cell Carcinoma Patients.” Cancer Immunology, Immunotherapy 70 (10): 2925–35. doi:10.1007/s00262-021-02885-9.